A tumor vaccine containing anti‐CD3 and anti‐CD28 bispecific antibodies triggers strong and durable antitumor activity in human lymphocytes

We recently reported on newly designed virus‐targeted bispecific CD3‐ and CD28‐binding molecules for human T‐cell activation. When bound via one arm to a human virus‐modified tumor cell vaccine, these reagents caused a polyclonal T‐cell response and overcame the potential various T‐cell evasion mech...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:International journal of cancer 2006-02, Vol.118 (3), p.658-667
Hauptverfasser: Haas, Claudia, Lulei, Maria, Fournier, Philippe, Arnold, Annette, Schirrmacher, Volker
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 667
container_issue 3
container_start_page 658
container_title International journal of cancer
container_volume 118
creator Haas, Claudia
Lulei, Maria
Fournier, Philippe
Arnold, Annette
Schirrmacher, Volker
description We recently reported on newly designed virus‐targeted bispecific CD3‐ and CD28‐binding molecules for human T‐cell activation. When bound via one arm to a human virus‐modified tumor cell vaccine, these reagents caused a polyclonal T‐cell response and overcame the potential various T‐cell evasion mechanisms of tumor cells. In our current study, we demonstrated the induction of strong antitumor activity in human lymphocytes upon coincubation with a virus‐modified tumor vaccine containing anti‐CD3 and anti‐CD28 bispecific antibodies. Blood mononuclear cells or purified T cells that were coincubated with such a tumor vaccine for 3 days were able to destroy monolayers of human breast carcinoma and other carcinoma cells. Serial transfer to new tumor cell monolayers revealed antitumor cytotoxic activity in such effector cells that lasted for about 10 days. Nontumor target cells appeared to be much less sensitive to the activated effector cells. Although the bispecific molecules alone did not activate effector cells, their binding to virus‐infected tumor cells was important and more effective than their binding to free virus. Antitumor activity of the activated effector cells was mediated through soluble factors as well as through direct cell contact of effector cells with the nontargeted bystander tumor cells. Since the virus‐modified tumor vaccine is well tolerated and already exhibits a certain effectiveness in cancer patients, the combination with new bispecific molecules has the potential to introduce additional antitumor effects. The reagents can also be combined with Newcastle Disease Virus (NDV)‐based oncolytic virotherapy. © 2005 Wiley‐Liss, Inc.
doi_str_mv 10.1002/ijc.21390
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_70193389</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>70193389</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3530-9ed135c5dd37afe7900d1fa8d16b3964697cd28e39680a346ad5dfdeef4a5eb13</originalsourceid><addsrcrecordid>eNp1kM1u1DAUhS0EokNhwQsgb0BikfbeeJzEy2qgUFSpm7KOHPtm6ipxBttplR1vAM_YJyGdjDQrVvfv0zm6h7H3CGcIkJ-7e3OWo1Dwgq0QVJlBjvIlW803yEoUxQl7E-M9AKKE9Wt2ggVCBShX7M8FT2M_BP6gjXGeuBl80s47v-XaJ_f0--_mi5hbexzzijcu7si41pn9uhmso8hTcNsthchjCsNewHI7Bt10tMcWJ22Se3Bp4s7zu7HXnndTv7sbzJQovmWvWt1Feneop-zn5dfbzffs-ubb1ebiOjNCCsgUWRTSSGtFqVsqFYDFVlcWi0aoYl2o0ti8ormvQIt1oa20rSVq11pSg-KUfVp0d2H4NVJMde-ioa7TnoYx1iWgEqJSM_h5AU0YYgzU1rvgeh2mGqF-Tr-e06_36c_sh4Po2PRkj-Qh7hn4eAB0NLprg_bGxSNXSjV_98ydL9yj62j6v2N99WOzWP8DmeOf2Q</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>70193389</pqid></control><display><type>article</type><title>A tumor vaccine containing anti‐CD3 and anti‐CD28 bispecific antibodies triggers strong and durable antitumor activity in human lymphocytes</title><source>MEDLINE</source><source>EZB Electronic Journals Library</source><source>Wiley Blackwell Journals</source><creator>Haas, Claudia ; Lulei, Maria ; Fournier, Philippe ; Arnold, Annette ; Schirrmacher, Volker</creator><creatorcontrib>Haas, Claudia ; Lulei, Maria ; Fournier, Philippe ; Arnold, Annette ; Schirrmacher, Volker</creatorcontrib><description>We recently reported on newly designed virus‐targeted bispecific CD3‐ and CD28‐binding molecules for human T‐cell activation. When bound via one arm to a human virus‐modified tumor cell vaccine, these reagents caused a polyclonal T‐cell response and overcame the potential various T‐cell evasion mechanisms of tumor cells. In our current study, we demonstrated the induction of strong antitumor activity in human lymphocytes upon coincubation with a virus‐modified tumor vaccine containing anti‐CD3 and anti‐CD28 bispecific antibodies. Blood mononuclear cells or purified T cells that were coincubated with such a tumor vaccine for 3 days were able to destroy monolayers of human breast carcinoma and other carcinoma cells. Serial transfer to new tumor cell monolayers revealed antitumor cytotoxic activity in such effector cells that lasted for about 10 days. Nontumor target cells appeared to be much less sensitive to the activated effector cells. Although the bispecific molecules alone did not activate effector cells, their binding to virus‐infected tumor cells was important and more effective than their binding to free virus. Antitumor activity of the activated effector cells was mediated through soluble factors as well as through direct cell contact of effector cells with the nontargeted bystander tumor cells. Since the virus‐modified tumor vaccine is well tolerated and already exhibits a certain effectiveness in cancer patients, the combination with new bispecific molecules has the potential to introduce additional antitumor effects. The reagents can also be combined with Newcastle Disease Virus (NDV)‐based oncolytic virotherapy. © 2005 Wiley‐Liss, Inc.</description><identifier>ISSN: 0020-7136</identifier><identifier>EISSN: 1097-0215</identifier><identifier>DOI: 10.1002/ijc.21390</identifier><identifier>PMID: 16108015</identifier><identifier>CODEN: IJCNAW</identifier><language>eng</language><publisher>Hoboken: Wiley Subscription Services, Inc., A Wiley Company</publisher><subject>Antibodies, Bispecific - immunology ; Antineoplastic agents ; Biological and medical sciences ; bispecific single‐chain antibodies ; Breast Neoplasms - immunology ; Breast Neoplasms - therapy ; Cancer Vaccines ; CD28 Antigens - immunology ; CD3 and CD28 cross‐linking ; CD3 Complex - immunology ; Cell Proliferation ; Female ; Humans ; Hybridomas ; Immunophenotyping ; Immunotherapy ; Lymphocyte Activation ; Lymphocyte Culture Test, Mixed ; Medical sciences ; Newcastle Disease Virus ; Pharmacology. Drug treatments ; T-Lymphocytes - immunology ; Tumor Cells, Cultured ; tumor neutralization assay ; Tumors</subject><ispartof>International journal of cancer, 2006-02, Vol.118 (3), p.658-667</ispartof><rights>Copyright © 2005 Wiley‐Liss, Inc.</rights><rights>2006 INIST-CNRS</rights><rights>Copyright 2005 Wiley-Liss, Inc.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3530-9ed135c5dd37afe7900d1fa8d16b3964697cd28e39680a346ad5dfdeef4a5eb13</citedby><cites>FETCH-LOGICAL-c3530-9ed135c5dd37afe7900d1fa8d16b3964697cd28e39680a346ad5dfdeef4a5eb13</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1002%2Fijc.21390$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1002%2Fijc.21390$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,780,784,1417,27924,27925,45574,45575</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=17595305$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/16108015$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Haas, Claudia</creatorcontrib><creatorcontrib>Lulei, Maria</creatorcontrib><creatorcontrib>Fournier, Philippe</creatorcontrib><creatorcontrib>Arnold, Annette</creatorcontrib><creatorcontrib>Schirrmacher, Volker</creatorcontrib><title>A tumor vaccine containing anti‐CD3 and anti‐CD28 bispecific antibodies triggers strong and durable antitumor activity in human lymphocytes</title><title>International journal of cancer</title><addtitle>Int J Cancer</addtitle><description>We recently reported on newly designed virus‐targeted bispecific CD3‐ and CD28‐binding molecules for human T‐cell activation. When bound via one arm to a human virus‐modified tumor cell vaccine, these reagents caused a polyclonal T‐cell response and overcame the potential various T‐cell evasion mechanisms of tumor cells. In our current study, we demonstrated the induction of strong antitumor activity in human lymphocytes upon coincubation with a virus‐modified tumor vaccine containing anti‐CD3 and anti‐CD28 bispecific antibodies. Blood mononuclear cells or purified T cells that were coincubated with such a tumor vaccine for 3 days were able to destroy monolayers of human breast carcinoma and other carcinoma cells. Serial transfer to new tumor cell monolayers revealed antitumor cytotoxic activity in such effector cells that lasted for about 10 days. Nontumor target cells appeared to be much less sensitive to the activated effector cells. Although the bispecific molecules alone did not activate effector cells, their binding to virus‐infected tumor cells was important and more effective than their binding to free virus. Antitumor activity of the activated effector cells was mediated through soluble factors as well as through direct cell contact of effector cells with the nontargeted bystander tumor cells. Since the virus‐modified tumor vaccine is well tolerated and already exhibits a certain effectiveness in cancer patients, the combination with new bispecific molecules has the potential to introduce additional antitumor effects. The reagents can also be combined with Newcastle Disease Virus (NDV)‐based oncolytic virotherapy. © 2005 Wiley‐Liss, Inc.</description><subject>Antibodies, Bispecific - immunology</subject><subject>Antineoplastic agents</subject><subject>Biological and medical sciences</subject><subject>bispecific single‐chain antibodies</subject><subject>Breast Neoplasms - immunology</subject><subject>Breast Neoplasms - therapy</subject><subject>Cancer Vaccines</subject><subject>CD28 Antigens - immunology</subject><subject>CD3 and CD28 cross‐linking</subject><subject>CD3 Complex - immunology</subject><subject>Cell Proliferation</subject><subject>Female</subject><subject>Humans</subject><subject>Hybridomas</subject><subject>Immunophenotyping</subject><subject>Immunotherapy</subject><subject>Lymphocyte Activation</subject><subject>Lymphocyte Culture Test, Mixed</subject><subject>Medical sciences</subject><subject>Newcastle Disease Virus</subject><subject>Pharmacology. Drug treatments</subject><subject>T-Lymphocytes - immunology</subject><subject>Tumor Cells, Cultured</subject><subject>tumor neutralization assay</subject><subject>Tumors</subject><issn>0020-7136</issn><issn>1097-0215</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2006</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp1kM1u1DAUhS0EokNhwQsgb0BikfbeeJzEy2qgUFSpm7KOHPtm6ipxBttplR1vAM_YJyGdjDQrVvfv0zm6h7H3CGcIkJ-7e3OWo1Dwgq0QVJlBjvIlW803yEoUxQl7E-M9AKKE9Wt2ggVCBShX7M8FT2M_BP6gjXGeuBl80s47v-XaJ_f0--_mi5hbexzzijcu7si41pn9uhmso8hTcNsthchjCsNewHI7Bt10tMcWJ22Se3Bp4s7zu7HXnndTv7sbzJQovmWvWt1Feneop-zn5dfbzffs-ubb1ebiOjNCCsgUWRTSSGtFqVsqFYDFVlcWi0aoYl2o0ti8ormvQIt1oa20rSVq11pSg-KUfVp0d2H4NVJMde-ioa7TnoYx1iWgEqJSM_h5AU0YYgzU1rvgeh2mGqF-Tr-e06_36c_sh4Po2PRkj-Qh7hn4eAB0NLprg_bGxSNXSjV_98ydL9yj62j6v2N99WOzWP8DmeOf2Q</recordid><startdate>20060201</startdate><enddate>20060201</enddate><creator>Haas, Claudia</creator><creator>Lulei, Maria</creator><creator>Fournier, Philippe</creator><creator>Arnold, Annette</creator><creator>Schirrmacher, Volker</creator><general>Wiley Subscription Services, Inc., A Wiley Company</general><general>Wiley-Liss</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20060201</creationdate><title>A tumor vaccine containing anti‐CD3 and anti‐CD28 bispecific antibodies triggers strong and durable antitumor activity in human lymphocytes</title><author>Haas, Claudia ; Lulei, Maria ; Fournier, Philippe ; Arnold, Annette ; Schirrmacher, Volker</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3530-9ed135c5dd37afe7900d1fa8d16b3964697cd28e39680a346ad5dfdeef4a5eb13</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2006</creationdate><topic>Antibodies, Bispecific - immunology</topic><topic>Antineoplastic agents</topic><topic>Biological and medical sciences</topic><topic>bispecific single‐chain antibodies</topic><topic>Breast Neoplasms - immunology</topic><topic>Breast Neoplasms - therapy</topic><topic>Cancer Vaccines</topic><topic>CD28 Antigens - immunology</topic><topic>CD3 and CD28 cross‐linking</topic><topic>CD3 Complex - immunology</topic><topic>Cell Proliferation</topic><topic>Female</topic><topic>Humans</topic><topic>Hybridomas</topic><topic>Immunophenotyping</topic><topic>Immunotherapy</topic><topic>Lymphocyte Activation</topic><topic>Lymphocyte Culture Test, Mixed</topic><topic>Medical sciences</topic><topic>Newcastle Disease Virus</topic><topic>Pharmacology. Drug treatments</topic><topic>T-Lymphocytes - immunology</topic><topic>Tumor Cells, Cultured</topic><topic>tumor neutralization assay</topic><topic>Tumors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Haas, Claudia</creatorcontrib><creatorcontrib>Lulei, Maria</creatorcontrib><creatorcontrib>Fournier, Philippe</creatorcontrib><creatorcontrib>Arnold, Annette</creatorcontrib><creatorcontrib>Schirrmacher, Volker</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>International journal of cancer</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Haas, Claudia</au><au>Lulei, Maria</au><au>Fournier, Philippe</au><au>Arnold, Annette</au><au>Schirrmacher, Volker</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>A tumor vaccine containing anti‐CD3 and anti‐CD28 bispecific antibodies triggers strong and durable antitumor activity in human lymphocytes</atitle><jtitle>International journal of cancer</jtitle><addtitle>Int J Cancer</addtitle><date>2006-02-01</date><risdate>2006</risdate><volume>118</volume><issue>3</issue><spage>658</spage><epage>667</epage><pages>658-667</pages><issn>0020-7136</issn><eissn>1097-0215</eissn><coden>IJCNAW</coden><abstract>We recently reported on newly designed virus‐targeted bispecific CD3‐ and CD28‐binding molecules for human T‐cell activation. When bound via one arm to a human virus‐modified tumor cell vaccine, these reagents caused a polyclonal T‐cell response and overcame the potential various T‐cell evasion mechanisms of tumor cells. In our current study, we demonstrated the induction of strong antitumor activity in human lymphocytes upon coincubation with a virus‐modified tumor vaccine containing anti‐CD3 and anti‐CD28 bispecific antibodies. Blood mononuclear cells or purified T cells that were coincubated with such a tumor vaccine for 3 days were able to destroy monolayers of human breast carcinoma and other carcinoma cells. Serial transfer to new tumor cell monolayers revealed antitumor cytotoxic activity in such effector cells that lasted for about 10 days. Nontumor target cells appeared to be much less sensitive to the activated effector cells. Although the bispecific molecules alone did not activate effector cells, their binding to virus‐infected tumor cells was important and more effective than their binding to free virus. Antitumor activity of the activated effector cells was mediated through soluble factors as well as through direct cell contact of effector cells with the nontargeted bystander tumor cells. Since the virus‐modified tumor vaccine is well tolerated and already exhibits a certain effectiveness in cancer patients, the combination with new bispecific molecules has the potential to introduce additional antitumor effects. The reagents can also be combined with Newcastle Disease Virus (NDV)‐based oncolytic virotherapy. © 2005 Wiley‐Liss, Inc.</abstract><cop>Hoboken</cop><pub>Wiley Subscription Services, Inc., A Wiley Company</pub><pmid>16108015</pmid><doi>10.1002/ijc.21390</doi><tpages>10</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0020-7136
ispartof International journal of cancer, 2006-02, Vol.118 (3), p.658-667
issn 0020-7136
1097-0215
language eng
recordid cdi_proquest_miscellaneous_70193389
source MEDLINE; EZB Electronic Journals Library; Wiley Blackwell Journals
subjects Antibodies, Bispecific - immunology
Antineoplastic agents
Biological and medical sciences
bispecific single‐chain antibodies
Breast Neoplasms - immunology
Breast Neoplasms - therapy
Cancer Vaccines
CD28 Antigens - immunology
CD3 and CD28 cross‐linking
CD3 Complex - immunology
Cell Proliferation
Female
Humans
Hybridomas
Immunophenotyping
Immunotherapy
Lymphocyte Activation
Lymphocyte Culture Test, Mixed
Medical sciences
Newcastle Disease Virus
Pharmacology. Drug treatments
T-Lymphocytes - immunology
Tumor Cells, Cultured
tumor neutralization assay
Tumors
title A tumor vaccine containing anti‐CD3 and anti‐CD28 bispecific antibodies triggers strong and durable antitumor activity in human lymphocytes
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-25T10%3A49%3A18IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=A%20tumor%20vaccine%20containing%20anti%E2%80%90CD3%20and%20anti%E2%80%90CD28%20bispecific%20antibodies%20triggers%20strong%20and%20durable%20antitumor%20activity%20in%20human%20lymphocytes&rft.jtitle=International%20journal%20of%20cancer&rft.au=Haas,%20Claudia&rft.date=2006-02-01&rft.volume=118&rft.issue=3&rft.spage=658&rft.epage=667&rft.pages=658-667&rft.issn=0020-7136&rft.eissn=1097-0215&rft.coden=IJCNAW&rft_id=info:doi/10.1002/ijc.21390&rft_dat=%3Cproquest_cross%3E70193389%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=70193389&rft_id=info:pmid/16108015&rfr_iscdi=true